https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-11-01 / Med. Pediatr. Oncol. 2003 Nov;41(5):478-80
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-11-01 / Med. Pediatr. Oncol. 2003 Nov;41(5):478-802003-11-01 00:00:002019-02-15 08:35:14Whole body thermochemotherapy in an infant with rhabdomyosarcoma and pulmonary metastases
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-11-01 / Z Gastroenterol 2003 Nov;41(11):1101-10
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-11-01 / Z Gastroenterol 2003 Nov;41(11):1101-102003-11-01 00:00:002019-02-15 09:13:25Immunobiology and gene-based immunotherapy of hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-11-01 / Klin Padiatr 2003 Nov-Dec;215(6):303-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-11-01 / Klin Padiatr 2003 Nov-Dec;215(6):303-92003-11-01 00:00:002003-11-01 00:00:00An approach for cure: PEI-chemotherapy and regional deep hyperthermia in children and adolescents with unresectable malignant tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-10-15 / J. Clin. Oncol. 2003 Oct;21(20):3826-35
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-10-15 / J. Clin. Oncol. 2003 Oct;21(20):3826-352003-10-15 00:00:002019-02-15 08:49:35Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-10-06 / Br. J. Cancer 2003 Oct;89(7):1172-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-10-06 / Br. J. Cancer 2003 Oct;89(7):1172-92003-10-06 00:00:002019-02-15 08:47:01Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-10-02 / Blood 2004 Feb;103(3):1026-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-10-02 / Blood 2004 Feb;103(3):1026-92003-10-02 00:00:002019-02-15 08:37:52Presence of functional dendritic cells in patients chronically infected with hepatitis C virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-10-01 / J. Hematother. Stem Cell Res. 2003 Oct;12(5):515-23
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-10-01 / J. Hematother. Stem Cell Res. 2003 Oct;12(5):515-232003-10-01 00:00:002003-10-01 00:00:00Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-10-01 / J. Virol. 2003 Oct;77(20):10862-71
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-10-01 / J. Virol. 2003 Oct;77(20):10862-712003-10-01 00:00:002019-02-15 08:37:53Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-10-01 / Clin. Cancer Res. 2003 Oct;9(12):4376-86
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-10-01 / Clin. Cancer Res. 2003 Oct;9(12):4376-862003-10-01 00:00:002019-02-15 08:50:28Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-10-01 / Melanoma Res. 2003 Oct;13(5):521-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-10-01 / Melanoma Res. 2003 Oct;13(5):521-302003-10-01 00:00:002019-02-15 08:49:36Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2
